Diversity Supplement to Tissue Engineering Strategies to Revitalize Allografts

Information

  • Research Project
  • 10405933
  • ApplicationId
    10405933
  • Core Project Number
    R01AR064200
  • Full Project Number
    3R01AR064200-07S1
  • Serial Number
    064200
  • FOA Number
    PA-21-071
  • Sub Project Id
  • Project Start Date
    3/1/2013 - 11 years ago
  • Project End Date
    6/30/2025 - a year from now
  • Program Officer Name
    MARQUITZ, ARON
  • Budget Start Date
    9/9/2021 - 2 years ago
  • Budget End Date
    6/30/2022 - a year ago
  • Fiscal Year
    2021
  • Support Year
    07
  • Suffix
    S1
  • Award Notice Date
    9/9/2021 - 2 years ago

Diversity Supplement to Tissue Engineering Strategies to Revitalize Allografts

Abstract: The goal of this Diversity supplement is the training of Sandra Castillo Aguirre. Specifically, her training will be undertaken via the research plan proposed. The work focuses on nanomaterials for bone regeneration, specifically to enhance the revitalization of bone allografts. Delayed union or nonunion, graft remodeling and repair, and metabolic bone diseases present critical needs for development of new technologies to enhance skeletal healing. While recent data reveal that Wnt signaling is essential for postnatal bone regeneration, delivery of Wnt agonists to support or enhance these endogenous mechanisms are limited due to short duration of action and off-target effects. Thus, a critical technological gap exists in developing specific drug delivery approaches for osteoprogenitors to modulate bone regenerative processes. Therefore, this work seeks to develop bone-selective nanomaterials designed to control Wnt agonist delivery and enhance bone regeneration in allograft-mediated reconstruction of massive bone defects. Our objective within this program is to (1) establish polymer nanotherapeutic requirements for targeting of remodeling bone allografts, (2) determine the required dose and longevity of osteoregenerative drug delivery to achieve cellular recruitment and bone regeneration in vitro, and (3) establish the regenerative efficacy of the drug delivery system in critical-sized bone defects. We hypothesize that resorption site-specific stimulation of bone regeneration can be achieved via targeted polymer therapeutic delivery of osteoanabolic Wnt agonists. The rationale for this work is to identify translatable therapies to selectively deliver osteoanabolic drugs to enhance bone regeneration. The long-term impact of this work is the development of polymer nanotherapeutics to target drugs to bone with high efficacy and specificity to promote bone graft healing and to rigorously train an underrepresented minority researcher in the field of therapeutic biomaterials and orthopaedic research.

IC Name
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
  • Activity
    R01
  • Administering IC
    AR
  • Application Type
    3
  • Direct Cost Amount
    32007
  • Indirect Cost Amount
    17284
  • Total Cost
    49291
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    846
  • Ed Inst. Type
    BIOMED ENGR/COL ENGR/ENGR STA
  • Funding ICs
    NIAMS:49291\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MTE
  • Study Section Name
    Musculoskeletal Tissue Engineering Study Section
  • Organization Name
    UNIVERSITY OF ROCHESTER
  • Organization Department
    BIOMEDICAL ENGINEERING
  • Organization DUNS
    041294109
  • Organization City
    ROCHESTER
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    146270140
  • Organization District
    UNITED STATES